• Hoechst 33342 for Mechanistic Cell Assays

  2026-09-04

  Hoechst 33342 is more than a nuclear stain: it can anchor quantitative cell-state measurements within receptor, inflammatory, and barrier-function studies. This guide explains how to interpret its DNA signal alongside the causal evidence from a recent GERD study without overclaiming what nuclear fluorescence can prove.

• Olsalazine Sodium: A Structure-to-Assay Framework

  2026-09-03

  Olsalazine Sodium is a mesalamine dimer that links LTB4-directed inflammation research with colorectal cancer tumor models and emerging xenobiotic-clearance assays. This article develops a structure-to-assay framework for separating chemical effects, transporter expression, and biological outcomes.

• Bafilomycin A1: Practical V-ATPase Workflows

  2026-09-03

  Use Bafilomycin A1 as a reversible V-ATPase inhibitor to dissect intracellular pH regulation, lysosomal turnover, osteoclast resorption, and endolysosomal limits in mRNA delivery. This workflow-centered guide covers dosing, controls, interpretation, and troubleshooting for reproducible cell-based assays.

• Structural Insights into CD38 CAR Affinity Tuning

  2026-09-02

  Cheng and colleagues resolve how the CD38-targeting CAR binders RP02 and 028 engage distinct antigen surfaces and alter CD38 enzymatic function. Their structure-guided attenuation of 028 reduced CAR-T fratricide while preserving cytotoxicity, providing a mechanistic framework for balancing affinity, target selectivity, and therapeutic activity.

• IEM-1925 in Soman-Induced Status Epilepticus

  2026-09-02

  A 2026 NeuroToxicology study evaluated glutamate receptor antagonists in a rat model of soman-induced status epilepticus. IEM-1925 combined sustained seizure control with improved survival, hippocampal protection, and behavioral outcomes, while also clarifying why AMPA/NMDA co-targeting may outperform transient benzodiazepine action in this setting.

• Protein A/G Magnetic Beads for IVDD Research

  2026-09-01

  Protein A/G Magnetic Beads provide a practical route for testing the MAPK1/HMOX1–mitophagy–pyroptosis model described in intervertebral disc degeneration research. This article translates the reference study into assay-selection, controls, and interpretation strategies for IP, co-IP, and related workflows.

• DIDS Workflows for Chloride and Cell-Fate Studies

  2026-09-01

  DIDS is a versatile anion transport inhibitor for connecting chloride-channel physiology with mitochondrial stress, vascular reactivity, TRPV1 signaling, and tumor-cell fate. This workflow emphasizes formulation control, dose-response design, orthogonal validation, and careful interpretation of near-death cancer-cell models.

• C8-HSL Drives Lung Cancer Progression via PI3K/AKT/ERK

  2026-08-31

  The reference study identifies the bacterial quorum-sensing signal C8-HSL as a potential regulator of lung cancer cell behavior, showing that it promotes H460 cell proliferation, migration, and invasion through PI3K/AKT/ERK pathway activation. Its findings connect microbial communication with tumor-cell aggressiveness and provide a rationale for investigating bacterial signals in microbial pathogenicity research and infection biology research.

• Anlotinib and Three-Kinase Angiogenesis Inhibition

  2026-08-30

  The reference study shows that anlotinib suppresses angiogenesis by simultaneously inhibiting VEGFR2, PDGFRβ, and FGFR1 activation and their shared ERK signaling output. Its combination of endothelial-cell assays, ex vivo vessel sprouting, and CAM experiments provides a mechanistic framework for studying multi-pathway angiogenesis inhibition in cancer research.

• Fluoxetine HCl Workflows for Serotonergic Research

  2026-08-29

  Build reproducible Fluoxetine HCl assays that connect serotonin transporter activity with 5HT2C signaling, neuroplasticity, and motivation. This guide combines concentration-aware molecular workflows with behavioral assay choices informed by developmental SSRI research.

• 6-Thioguanine Blocks EV71 via BIRC3 Autophagy

  2026-08-29

  A 2025 BMC Microbiology study identifies 6-thioguanine as an in vitro inhibitor of EV71 replication in HT-29 cells and links this activity to reduced BIRC3-mediated complete autophagy. The work provides a mechanistic basis for EV71 virus inhibition while highlighting the need for validation in additional cell systems, animal models, and clinically relevant exposure studies.

• Hepatic sEH–Nrf2 Signaling in Osteoporosis

  2026-08-28

  A 2025 Free Radical Biology and Medicine study identifies hepatic soluble epoxide hydrolase as a regulator of osteoclastogenesis through circulating epoxide metabolites and Nrf2-ARE signaling. Its combined clinical, mouse, cellular, transcriptomic, and genetic evidence supports a liver–bone redox axis, while also defining important limits for translation.

• 3X (DYKDDDDK) Peptide: NINJ1 Workflows

  2026-08-27

  Use the 3X FLAG peptide as a high-sensitivity control, competitive elution reagent, and assay-development tool for recombinant membrane proteins such as NINJ1. This guide connects FLAG-based purification and detection with membrane-disk biology while highlighting metal sensitivity, structural validation, and practical troubleshooting.

• TCAIM Controls OGDH and Mitochondrial Metabolism

  2026-08-27

  The 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds OGDH and promotes its reduction through HSPA9 and LONP1. This mechanism connects mitochondrial proteostasis with control of OGDH complex activity, carbohydrate catabolism, and broader metabolic state in cells and mice.

• Temozolomide Workflows for Glioma DNA-Damage Studies

  2026-08-26

  Temozolomide provides a reproducible DNA-damage challenge for glioma, DNA repair, and chemotherapy resistance experiments. Its strongest differentiation is the ability to pair a defined alkylation stimulus with ATRX-stratified RTK or PDGFR inhibitor assays.

455 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page